{"id":133197,"date":"2022-08-15T10:36:51","date_gmt":"2022-08-15T14:36:51","guid":{"rendered":"https:\/\/44.250.171.167\/?p=133197"},"modified":"2022-10-06T04:47:03","modified_gmt":"2022-10-06T08:47:03","slug":"divis-laboratories-ltd-q1-fy23-earnings-conference-call-insights","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/divis-laboratories-ltd-q1-fy23-earnings-conference-call-insights\/","title":{"rendered":"Divi&#8217;s Laboratories Ltd Q1 FY23 Earnings Conference Call Insights"},"content":{"rendered":"<p><iframe loading=\"lazy\" title=\"Divi&#039;s Laboratories Ltd Q1 FY23 Earnings Concall\" width=\"500\" height=\"375\" src=\"https:\/\/www.youtube.com\/embed\/EPaxfKgyoZQ?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p><strong>Key highlights from Divi&#8217;s Laboratories Ltd (<a href=\"https:\/\/44.250.171.167\/symbol\/DIVISLAB\/\">DIVISLAB<\/a>) Q1 FY23 Earnings Concall<\/strong><\/p>\n<p><strong>Q&amp;A Highlights:<\/strong><\/p>\n<ul>\n<li>Tushar Manudhane from Motilal Oswal asked about the stable sales in the generic side for the past 3 quarters, if capacity expansion will increase sales in coming quarters. Murali Divi MD said that with the expansion, the company will see increased sales in the generic portfolio.<\/li>\n<\/ul>\n<ul>\n<li>Surya Patra of PhillipCapital asked about margins, if there is sequentially any change in cost structure. Murali Divi MD replied that in productivity and efficiency there is no change, but raw material cost have gone up by 30% to 50% and the energy cost have also gone up with impacted margins.<\/li>\n<\/ul>\n<ul>\n<li>Shyam Srinivasan from Goldman Sachs asked about any product or customer concentration risk, with top products and customer going higher. \u00a0Murali Divi MD replied that going forward it will be more diversified and will go back to where it was.<\/li>\n<\/ul>\n<ul>\n<li>Shyam Srinivasan from Goldman Sachs asked about imports and how much of it the company is dependent from a material consumption perspective. Nilima Divi Director replied that the dependency on China is not totally gone, because they have the largest capacities in basic chemicals in the industry. The company believes costs will come down and situation will normalize.<\/li>\n<\/ul>\n<ul>\n<li>Cyndrella Carvalho from JM Financial asked if the generic run rate of about 870 should be improving from 2Q23 to rest of year. Murali Divi MD answered that the company doesn\u2019t want to speak on QonQ basis. In the next two years, the company will be able to see the upside and value addition.<\/li>\n<\/ul>\n<ul>\n<li>Cyndrella Carvalho from JM Financial enquired if there is any one-offs in the other expenses that elevated it in 1Q23. Murali Divi MD clarified that there is no one-off in 1Q, other than what the fast track projects have contributed in the last year.<\/li>\n<\/ul>\n<ul>\n<li>Cyndrella Carvalho from JM Financial also asked if it can be expected to have 40% EBITDA margin sustainable for FY23. Murali Divi MD answered that the company should be able to maintain the 40% EBITDA margin or better in FY23.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Key highlights from Divi&#8217;s Laboratories Ltd (DIVISLAB) Q1 FY23 Earnings Concall Q&amp;A Highlights: Tushar Manudhane from Motilal Oswal asked about the stable sales in the generic side for the past 3 quarters, if capacity expansion will increase sales in coming quarters. Murali Divi MD said that with the expansion, the company will see increased sales [&hellip;]<\/p>\n","protected":false},"author":1767,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"Divi's Laboratories Ltd Q1 FY23 Earnings Conference Call Insights #DIVISLAB #Q1 #FY23 #Earnings","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[9825,392,5747],"tags":[10304,10307,1115],"class_list":["post-133197","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings-call-highlights","category-earnings","category-healthcare-stocks","tag-api","tag-branded-drug","tag-pharmaceuticals"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":129961,"url":"https:\/\/alphastreet.com\/india\/divis-laboratories-ltd-q4-fy22-earnings-conference-call-insights\/","url_meta":{"origin":133197,"position":0},"title":"Divi&#8217;s Laboratories Ltd Q4 FY22 Earnings Conference Call Insights","author":"Praveen","date":"May 24, 2022","format":false,"excerpt":"https:\/\/youtu.be\/MLu1npKFqZg Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q4 FY22 Earnings Concall Management Update: DIVISLAB said it reached milestone revenue for FY22 of $1 billion with decent profitability despite the hurdles faced during the pandemic. Q&A Highlights: Tushar Manudhane of Motilal Oswal asked if the company\u2019s steady-state growth of 13-15%\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":147097,"url":"https:\/\/alphastreet.com\/india\/divis-laboratories-ltd-q4-fy23-earnings-conference-call-insights\/","url_meta":{"origin":133197,"position":1},"title":"Divi&#8217;s Laboratories Ltd Q4 FY23 Earnings Conference Call Insights","author":"Praveen","date":"May 23, 2023","format":false,"excerpt":"Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q4 FY23 Earnings Concall Q&A Highlights: [00:11:30] Tushar Manudhane from Motilal Oswal asked if backward integration and softening raw material prices lead to a new normal of 57-58% GM. Murali Divi MD replied that RM prices are decreasing, stabilizing, and expected to continue\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":135808,"url":"https:\/\/alphastreet.com\/india\/divis-laboratories-ltd-q2-fy23-earnings-conference-call-insights\/","url_meta":{"origin":133197,"position":2},"title":"Divi&#8217;s Laboratories Ltd Q2 FY23 Earnings Conference Call Insights","author":"Praveen","date":"November 8, 2022","format":false,"excerpt":"https:\/\/youtu.be\/e1-tljnhSVM Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q2 FY23 Earnings Concall Management Update: [00:06:48] DIVISLAB stated that though global logistics scenario has improved and is seeing receding sea and air-freight costs in 2Q23, minor disruptions stemming from issues like manpower shortages continues. [00:07:12] DIVISLAB also said that prices of\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":127343,"url":"https:\/\/alphastreet.com\/india\/divis-laboratories-ltd-q3-fy22-earnings-conference-call-insights\/","url_meta":{"origin":133197,"position":3},"title":"Divi&#8217;s Laboratories Ltd Q3 FY22 Earnings Conference Call Insights","author":"Praveen","date":"February 14, 2022","format":false,"excerpt":"https:\/\/www.youtube.com\/watch?v=E7EoiAKzMn0 Key highlights from Divi's Laboratories Ltd (DIVISLAB) Q3 FY22 Earnings Concall Management Update: The company capitalized INR196 crores in 3Q22 and anticipate another INR100 crore capex before end of FY22. Q&A Highlights: Tushar Manudhane from Motilal Oswal asked if there was any one-off for the sharp increase in revenue\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":133386,"url":"https:\/\/alphastreet.com\/india\/shriram-properties-ltd-q1-fy23-earnings-conference-call-insights\/","url_meta":{"origin":133197,"position":4},"title":"Shriram Properties Ltd Q1 FY23 Earnings Conference Call Insights","author":"Praveen","date":"August 17, 2022","format":false,"excerpt":"https:\/\/youtu.be\/L3Etjy1u_70 Key highlights from Shriram Properties Ltd (SHRIRAMPPS) Q1 FY23 Earnings Concall Management Update: SHRIRAMPPS said the company saw some softening compared to 4Q22 due to seasonality. However YonY, the company saw a very strong growth in demand. Q&A Highlights: Chaitanya Shah from Silverlight asked about the timeline of cash\u2026","rel":"","context":"In &quot;Concall Highlights&quot;","block_context":{"text":"Concall Highlights","link":"https:\/\/alphastreet.com\/india\/category\/earnings-call-highlights\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":133571,"url":"https:\/\/alphastreet.com\/india\/divis-laboratories-ltd-divislab-q1-fy23-earnings-concall-transcript\/","url_meta":{"origin":133197,"position":5},"title":"Divi&#8217;s Laboratories Ltd (DIVISLAB) Q1 FY23 Earnings Concall Transcript","author":"IRS_INDIA","date":"August 12, 2022","format":false,"excerpt":"Divi's Laboratories Ltd (NSE:DIVISLAB) Q1 FY23 Earnings Concall dated Aug. 12, 2022 Corporate Participants: Satish Choudhury -- Company Secretary and Chief Investor Relations Officer Murali K. Divi -- Managing Director Nilima Divi -- Whole-Time Director, Commercial Analysts: Tushar Manudhane -- Motilal Oswal Financial Services -- Analyst Surya Narayan Patra --\u2026","rel":"","context":"In &quot;Earnings Call Transcripts&quot;","block_context":{"text":"Earnings Call Transcripts","link":"https:\/\/alphastreet.com\/india\/category\/transcripts\/"},"img":{"alt_text":"Earnings Conference Call Transcript","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2020\/09\/Transcript-thumbnail-e1657213425955.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/133197","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1767"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=133197"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/133197\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=133197"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=133197"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=133197"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}